. | Clinical practice guidelines . | Expert consensus statements . | Clinical statements/white papers . |
---|---|---|---|
Definition | Evidence-based documents containing systematically developed recommendations with an explicit clinical scope and explicit consideration of benefits, harms, values, and preferences. | Expert position on a controversial or specific clinical topic, formulated as a statement of facts based on available evidence and expert consensus in situations where high-level evidence is unavailable. | Extensive reports outlining positions on critical clinical issues while highlighting areas of ongoing uncertainty or concern for patient safety. |
Source of evidence | Randomized controlled trials (RCTs) are available and serve as the primary source of information; observational data are used if considered robust. | Robust observational data are available and serve as the primary source of information in conjunction with a limited number of RCTs. | Any research and health care regulations |
Number of writing committee members | Up to 20 | Up to 20 | Up to 10 |
Review | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, up to 3 anonymous reviewers from each participating entity |
Length | Up to 30,000 words and a total of 500 references | Up to 15,000 words and a total of 300 references | Up to 5000 words and a total of 50 references |
Time frame | 24 months | 12 months | 6 months |
. | Clinical practice guidelines . | Expert consensus statements . | Clinical statements/white papers . |
---|---|---|---|
Definition | Evidence-based documents containing systematically developed recommendations with an explicit clinical scope and explicit consideration of benefits, harms, values, and preferences. | Expert position on a controversial or specific clinical topic, formulated as a statement of facts based on available evidence and expert consensus in situations where high-level evidence is unavailable. | Extensive reports outlining positions on critical clinical issues while highlighting areas of ongoing uncertainty or concern for patient safety. |
Source of evidence | Randomized controlled trials (RCTs) are available and serve as the primary source of information; observational data are used if considered robust. | Robust observational data are available and serve as the primary source of information in conjunction with a limited number of RCTs. | Any research and health care regulations |
Number of writing committee members | Up to 20 | Up to 20 | Up to 10 |
Review | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, up to 3 anonymous reviewers from each participating entity |
Length | Up to 30,000 words and a total of 500 references | Up to 15,000 words and a total of 300 references | Up to 5000 words and a total of 50 references |
Time frame | 24 months | 12 months | 6 months |
. | Clinical practice guidelines . | Expert consensus statements . | Clinical statements/white papers . |
---|---|---|---|
Definition | Evidence-based documents containing systematically developed recommendations with an explicit clinical scope and explicit consideration of benefits, harms, values, and preferences. | Expert position on a controversial or specific clinical topic, formulated as a statement of facts based on available evidence and expert consensus in situations where high-level evidence is unavailable. | Extensive reports outlining positions on critical clinical issues while highlighting areas of ongoing uncertainty or concern for patient safety. |
Source of evidence | Randomized controlled trials (RCTs) are available and serve as the primary source of information; observational data are used if considered robust. | Robust observational data are available and serve as the primary source of information in conjunction with a limited number of RCTs. | Any research and health care regulations |
Number of writing committee members | Up to 20 | Up to 20 | Up to 10 |
Review | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, up to 3 anonymous reviewers from each participating entity |
Length | Up to 30,000 words and a total of 500 references | Up to 15,000 words and a total of 300 references | Up to 5000 words and a total of 50 references |
Time frame | 24 months | 12 months | 6 months |
. | Clinical practice guidelines . | Expert consensus statements . | Clinical statements/white papers . |
---|---|---|---|
Definition | Evidence-based documents containing systematically developed recommendations with an explicit clinical scope and explicit consideration of benefits, harms, values, and preferences. | Expert position on a controversial or specific clinical topic, formulated as a statement of facts based on available evidence and expert consensus in situations where high-level evidence is unavailable. | Extensive reports outlining positions on critical clinical issues while highlighting areas of ongoing uncertainty or concern for patient safety. |
Source of evidence | Randomized controlled trials (RCTs) are available and serve as the primary source of information; observational data are used if considered robust. | Robust observational data are available and serve as the primary source of information in conjunction with a limited number of RCTs. | Any research and health care regulations |
Number of writing committee members | Up to 20 | Up to 20 | Up to 10 |
Review | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, a lead reviewer and up to 5 anonymous reviewers from each participating entity in collaboration with the governing bodies | Following the writing committee's established composition principles, up to 3 anonymous reviewers from each participating entity |
Length | Up to 30,000 words and a total of 500 references | Up to 15,000 words and a total of 300 references | Up to 5000 words and a total of 50 references |
Time frame | 24 months | 12 months | 6 months |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.